Galway MedTech company SymPhysis Medical has secured €2.2m funding for the development of a device to address the condition of fluid in the chest of cancer patients. The medtech company will seek regulatory approval in the US for its device treating end-of-life cancer patients at the end of 2025. Business Post Article
Sigrid Therapeutics today announced the market readiness of SiPore® for both the professional and consumer oral health markets. Read Press Release here
Signum Surgical, a medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce that its BioHealxTM technology has been granted marketing clearance by the U.S. Food and Drug Administration (FDA), as a first-of-its-kind medical device for the treatment of anal fistula. Read Press Release here
Irish medtech firm Deciphex has signed a collaboration agreement with Novartis, the pharma giant, to develop artificial intelligence solutions to aid drug discovery and development. Read Full Article
CroíValve announced today that it began an early feasibility study for its Duo tricuspid coaptation valve system. The beginning of the study follows FDA investigational device (IDE) approval. Read Full Article
The Spiddal company is to recruit six staff across research and development, manufacturing, project management, clinical affairs, and commercial strategy. The majority of the new roles will be based in Ireland, with commercial and clinical roles spread across the United States and Europe to support international growth. Read Full Article
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication Read Full Article
Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid's innovative SiPore® technology. Read Full Article
Deciphex, a trailblazer in digital pathology solutions, is delighted to announce a successful €10m venture debt financing round. This strategic investment will fuel the company's capacity growth, headcount increase, service enhancement, and expansion to new markets, addressing the growing global demand in pathology services. Read Full Article
Cinclus Pharma Holding AB (publ) ("Cinclus Pharma"), a pharma company focused on the development of a novel treatment for gastroesophageal reflux disease ("GERD"), today announces that two abstracts from the company's phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD ("eGERD"), are being presented at the leading gastro conference United European Gastroenterology ("UEG") which is held in Copenhagen 14 – 17 October 2023. Read Press Release here
